Your browser doesn't support javascript.
loading
An interrupted time series study of electronic health record clinical decision support for providers caring for patients with atrial fibrillation at increased stroke risk.
Osterland, Andrew J; Yasuda, Marie; Widmer, Robert J; Colavecchia, Anthony C; Gums, Tyler; Emir, Birol; Nolen, Kim; MacLean, Elizabeth; Godley, Paul J.
Afiliação
  • Osterland AJ; Baylor Scott & White Health, Temple, TX, USA.
  • Yasuda M; Baylor Scott & White Health, Temple, TX, USA.
  • Widmer RJ; Baylor Scott & White Health, Temple, TX, USA.
  • Colavecchia AC; Pfizer Inc., New York, NY, USA.
  • Gums T; Pfizer Inc., New York, NY, USA.
  • Emir B; Pfizer Inc., New York, NY, USA.
  • Nolen K; Pfizer Inc., New York, NY, USA.
  • MacLean E; Pfizer Inc., New York, NY, USA.
  • Godley PJ; Baylor Scott & White Health, Temple, TX, USA.
Am J Health Syst Pharm ; 80(24): 1830-1839, 2023 Dec 05.
Article em En | MEDLINE | ID: mdl-37696764
PURPOSE: To measure the effect of clinical decision support (CDS) on anticoagulation rates in patients with atrial fibrillation (AFib) or atrial flutter (AFlut) at high stroke risk and receiving care in outpatient settings, and to assess provider response to CDS. METHODS: This observational, quasi-experimental, interrupted time series study utilized electronic health record data at a large integrated delivery network in Texas from April to November 2020. CDS consisted of an electronic Best Practice Advisory (BPA)/alert (Epic Systems Corporation, Verona, WI) with links to 2 AFib order sets displayed to providers in outpatient settings caring for non-anticoagulated patients with AFib and elevated CHA2DS2VASc scores. Weekly outpatient anticoagulation rates were assessed in patients with high stroke risk before and after implementation of CDS. Alert actions and acknowledgment reasons were evaluated descriptively. RESULTS: Mean (SD) weekly counts of eligible patients were 8,917 (566) before and 8,881 (811) after implementation. Weekly anticoagulation rates increased during the pre-BPA study period (ß1 = 0.07%; SE, 0.02%; P = 0.0062); however, there were no significant changes in the level (ß2 = 0.60%; SE, 0.42%; P = 0.1651) or trend (ß3 = -0.01%; SE, 0.05%; P = 0.8256) of anticoagulation rates associated with CDS implementation. In encounters with the BPA/alert displayed (n = 17,654), acknowledgment reasons were provided in 4,473 (25.3%) of the encounters, with prescribers most commonly citing bleeding risk (n = 1,327, 7.5%) and fall risk (n = 855, 4.8%). CONCLUSION: There was a significant trend of increasing anticoagulation rates during the pre-BPA period, with no significant change in trend during the post-BPA period relative to the pre-BPA period.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Sistemas de Apoio a Decisões Clínicas / Acidente Vascular Cerebral Tipo de estudo: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Am J Health Syst Pharm Assunto da revista: FARMACIA / HOSPITAIS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Sistemas de Apoio a Decisões Clínicas / Acidente Vascular Cerebral Tipo de estudo: Etiology_studies / Guideline / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Am J Health Syst Pharm Assunto da revista: FARMACIA / HOSPITAIS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos